Back to Trials
NCT06408207NARecruiting

CGM Academy for Youth With Type 1 Diabetes

Children's Hospital Los Angeles

Start Date

5/1/2025

Completion Date

12/30/2026

Summary

The goal of this randomized clinical trial is to compare the effects of a virtual education curriculum in blood glucose variation of youth with type 1 diabetes wearing continuous glucose monitoring (CGM) device. The main questions the study aims to answer are: * Do participants undertaking the proposed curriculum present improved glucose variation than participants of standard education? * Explore relationships between participant's glycemic outcomes with diabetes distress, diabetes family responsibilities, and number of hours of diabetes education. Participants in the intervention group will: * receive an interactive workbook with problem-based learning scenarios and video links about CGM and glucose management strategies. * participate in four in-depth online group sessions with diabetes care and education specialists * complete questionnaires three times: at the time of study enrollment, week 4 and 6 months. Participants in the comparison group will: * receive standard education provided to all patients at CHLA * complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.

Detailed Description

Youth with type 1 diabetes (T1D) are at increased risk for kidney failure, vision loss, heart disease, and premature mortality due to challenges with glycemic excursions. Continuous glucose monitoring (CGM) systems represent an important advance in diabetes technology with significant advantages over self-monitored blood glucose and the potential to optimize glycemic management. Despite these advances, youth with T1D, including patients at Children's Hospital Los Angeles (CHLA), fail to achieve recommended glycemic targets, highlighting the opportunity for testing innovative diabetes education programs aimed at increased technology uptake such as the CGM Academy intervention.

Eligibility Criteria

Age Range: 8 years to 18 years

Inclusion Criteria: * Current age of 8-18 years, age group eligible for CGM therapy with Dexcom G6 and G7 * T1D duration ≥6 months, as insulin adjustments during honeymoon stage differs from establishedT1D * Able to speak, read, and write English or Spanish * Smartphone compatible with Dexcom G6 and G7application * Ability to participate in virtual visits Exclusion Criteria: • Known history of medical adhesive allergies

Interventions

BEHAVIORAL

CGM Academy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Type1 Diabetes

Locations

Children's Hospital Los Angeles

Los Angeles, California 90027

United States